Iron deficiency may be linked to non-dialysis-dependent chronic kidney disease and mortality in patients without anemia, according to results of a nationwide cohort study.While iron is a key component ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Chronic kidney disease (CKD) is a growing global health concern, significantly contributing to morbidity and mortality rates worldwide. Characterized by a ...

ProKidney’s Rilparencel shows promise for CKD patients, with Phase 2 data expected in 2025. Learn why PROK stock is a “Buy” ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

The FDA has approved Ozempic to reduce kidney failure risk in people with type 2 diabetes and chronic kidney disease. Studies ...

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...

Climate change is increasing the risk of urological diseases, including cancer and kidney conditions, while urological ...

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

A popular diabetes drug just got a major new approval—and it could be a game-changer for millions of Americans at risk for ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...